Structure Therapeutics (NASDAQ:GPCR - Get Free Report) announced its earnings results on Thursday. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.01, Zacks reports.
Structure Therapeutics Stock Performance
Shares of NASDAQ:GPCR traded down $1.41 on Monday, hitting $22.34. The stock had a trading volume of 1,426,485 shares, compared to its average volume of 832,982. Structure Therapeutics has a twelve month low of $19.61 and a twelve month high of $62.74. The firm's 50 day moving average price is $26.45 and its 200-day moving average price is $33.47. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -30.19 and a beta of -2.75.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on GPCR shares. Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday. They issued an "outperform" rating on the stock. Finally, JMP Securities reissued a "market outperform" rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $81.29.
View Our Latest Report on Structure Therapeutics
Structure Therapeutics Company Profile
(
Get Free Report)
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
See Also
Before you consider Structure Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.
While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
